News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,926 Results
Type
Article (41124)
Company Profile (250)
Press Release (663552)
Multimedia
Podcasts (54)
Webinars (12)
Section
Business (206626)
Career Advice (2124)
Deals (35844)
Drug Delivery (102)
Drug Development (81602)
Employer Resources (175)
FDA (16253)
Job Trends (14948)
News (348878)
Policy (32947)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2591)
Accelerated approval (5)
Adcomms (20)
Allergies (82)
Alliances (49754)
ALS (89)
Alzheimer's disease (1381)
Antibody-drug conjugate (ADC) (114)
Approvals (16248)
Artificial intelligence (244)
Autoimmune disease (22)
Automation (15)
Bankruptcy (366)
Best Places to Work (11692)
BIOSECURE Act (18)
Biosimilars (105)
Biotechnology (176)
Bladder cancer (61)
Brain cancer (26)
Breast cancer (264)
Cancer (2095)
Cardiovascular disease (167)
Career advice (1776)
Career pathing (29)
CAR-T (143)
Cell therapy (407)
Cervical cancer (19)
Clinical research (66228)
Collaboration (801)
Compensation (508)
Complete response letters (20)
COVID-19 (2620)
CRISPR (37)
C-suite (228)
Cystic fibrosis (100)
Data (2053)
Decentralized trials (2)
Denatured (19)
Depression (42)
Diabetes (257)
Diagnostics (6385)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (119)
Drug pricing (98)
Drug shortages (27)
Duchenne muscular dystrophy (94)
Earnings (87424)
Editorial (39)
Employer branding (21)
Employer resources (149)
Events (112915)
Executive appointments (708)
FDA (17439)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (726)
Gene editing (100)
Generative AI (19)
Gene therapy (290)
GLP-1 (713)
Government (4503)
Grass and pollen (4)
Guidances (51)
Healthcare (18995)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (111)
Indications (26)
Infectious disease (2761)
Inflammatory bowel disease (134)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (92)
Interviews (333)
IPO (16635)
IRA (40)
Job creations (3672)
Job search strategy (1508)
Kidney cancer (9)
Labor market (36)
Layoffs (465)
Leadership (16)
Legal (8030)
Liver cancer (72)
Lung cancer (303)
Lymphoma (139)
Machine learning (5)
Management (58)
Manufacturing (294)
MASH (64)
Medical device (13436)
Medtech (13441)
Mergers & acquisitions (19723)
Metabolic disorders (664)
Multiple sclerosis (77)
NASH (16)
Neurodegenerative disease (86)
Neuropsychiatric disorders (24)
Neuroscience (1896)
NextGen: Class of 2025 (6572)
Non-profit (4515)
Northern California (2540)
Now hiring (38)
Obesity (359)
Opinion (211)
Ovarian cancer (73)
Pain (81)
Pancreatic cancer (81)
Parkinson's disease (148)
Partnered (21)
Patents (224)
Patient recruitment (99)
Peanut (46)
People (58142)
Pharmaceutical (65)
Pharmacy benefit managers (20)
Phase I (20630)
Phase II (29156)
Phase III (21746)
Pipeline (1120)
Policy (133)
Postmarket research (2607)
Preclinical (8736)
Press Release (66)
Prostate cancer (99)
Psychedelics (33)
Radiopharmaceuticals (251)
Rare diseases (374)
Real estate (5964)
Recruiting (67)
Regulatory (22430)
Reports (46)
Research institute (2349)
Resumes & cover letters (361)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (67)
Series A (126)
Series B (82)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2188)
Special edition (15)
Spinal muscular atrophy (148)
Sponsored (28)
Startups (3620)
State (2)
Stomach cancer (13)
Supply chain (66)
Tariffs (24)
The Weekly (33)
United States (22119)
Vaccines (682)
Venture capitalists (38)
Weight loss (234)
Women's health (35)
Worklife (15)
Date
Last 7 days (472)
Last 30 days (2166)
Last 365 days (33015)
2025 (9278)
2024 (35467)
2023 (40359)
2022 (51465)
2021 (55991)
2020 (54429)
2019 (46947)
2018 (35377)
2017 (32490)
2016 (31931)
2015 (37949)
2014 (31731)
2013 (26770)
2012 (29002)
2011 (29676)
2010 (27738)
Location
Africa (750)
Alabama (52)
Alaska (7)
Arizona (232)
Arkansas (14)
Asia (38563)
Australia (6334)
California (5795)
Canada (1945)
China (496)
Colorado (258)
Connecticut (266)
Delaware (135)
Europe (83008)
Florida (862)
Georgia (204)
Idaho (57)
Illinois (518)
India (25)
Indiana (301)
Iowa (9)
Japan (151)
Kansas (102)
Kentucky (23)
Louisiana (9)
Maine (62)
Maryland (857)
Massachusetts (4358)
Michigan (215)
Minnesota (379)
Mississippi (2)
Missouri (78)
Montana (27)
Nebraska (25)
Nevada (60)
New Hampshire (62)
New Jersey (1678)
New Mexico (28)
New York (1657)
North Carolina (955)
North Dakota (7)
Northern California (2540)
Ohio (198)
Oklahoma (14)
Oregon (33)
Pennsylvania (1307)
Puerto Rico (11)
Rhode Island (30)
South America (1124)
South Carolina (20)
South Dakota (1)
Southern California (2188)
Tennessee (99)
Texas (861)
Utah (173)
Virginia (135)
Washington D.C. (61)
Washington State (531)
West Virginia (3)
Wisconsin (51)
704,926 Results for "rapamycin holdings inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
February 10, 2025
·
7 min read
Press Releases
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use
February 24, 2025
·
6 min read
Press Releases
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
January 9, 2025
·
7 min read
Press Releases
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
March 4, 2025
·
8 min read
Press Releases
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
January 10, 2025
·
8 min read
Press Releases
Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University’s Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology
April 14, 2025
·
9 min read
Press Releases
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
November 7, 2024
·
8 min read
FDA
Palvella Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
Palvella Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations (Microcystic LMs).
November 16, 2023
·
4 min read
Press Releases
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
April 14, 2025
·
3 min read
Press Releases
Adagio Medical Holdings, Inc. Receives FDA Breakthrough Device Designation for the vCLASTM Cryoablation System
April 17, 2025
·
5 min read
1 of 70,493
Next
